Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Capricor Therapeutics' stock soared 500% after its drug met key trial goals, reversing an earlier FDA setback.

flag Capricor Therapeutics' stock surged up to 500% after its Phase 3 HOPE-3 trial showed Deramiocel, a cell therapy for Duchenne muscular dystrophy, met primary and secondary endpoints, improving heart function. flag The results reversed a July 2024 FDA rejection that had caused a sharp decline. flag The company launched a public equity offering to capitalize on the momentum. flag Meanwhile, silver prices hit a record high above $58 per ounce, driven by strong industrial demand, especially from solar energy, with analysts predicting continued growth into 2026 or 2027. flag NEXTDC signed a deal with OpenAI to build a hyperscale AI campus in Sydney, boosting its shares 8%. flag The World Gold Council forecasts gold volatility in 2026, with a likely 5% to 15% rise amid safe-haven demand, though risks remain from inflation and geopolitical tensions. flag Critical Resources advanced exploration at its Cap Burn and Amoco projects, with promising drill results and regulatory progress.

6 Articles